Text

Chapter 48 In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei

---

Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it may take several months after treatment before surviving parasites become detectable in the blood. To expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive wholebody bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2).

---

Availability

No copy data

Detail Information

Series Title

-

Call Number

-

Publisher

: Springer Nature., 2020

Collation

-

Language

English

ISBN/ISSN

9781071602935

Classification

NONE

Content Type

text

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Firefly luciferase
Trypanosoma brucei brucei
In vivo imaging
Bioluminescence

Specific Detail Info

-

Statement of Responsibility

-

Other Information

Cataloger

Candra

Source

-

Validator

-

Digital Object Identifier (DOI)

https://doi.org/10.1007/978-1-0716-0294-2_48

Journal Volume

-

Journal Issue

-

Subtitle

-

Parallel Title

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment